Severe Eosinophilic Asthma Treatment | FASENRA® (benralizumab) Subcutaneous Injection
FASENRA® (benralizumab) is an add-on maintenance treatment for patients 6 and older who are diagnosed with severe eosinophilic asthma.
Total Visits
Avg. Visit Duration
Pages per Visit
Bounce Rate
Registration Date
| Month | Traffic |
|---|---|
| 2025-02 | 45.784 |
| 2025-03 | 47.193 |
| 2025-04 | 55.157 |
| 2025-05 | 75.118 |
| Source | Traffic Share |
|---|---|
| search | 56.70% |
| direct | 31.29% |
| paid referrals | 6.54% |
| referrals | 3.90% |
| social | 1.49% |
| 0.07% |
| Region | Percentage |
|---|---|
| United States | 89.54% |
| United Kingdom | 5.17% |
| Australia | 4.73% |
| India | 0.56% |
| Keyword | Traffic | Volume | CPC |
|---|---|---|---|
| fasenra | 754 | 7,540 | $7.64 |
| lung specialist in newbury park,ca | 5 | 50 | $0.00 |
| pulmonary doctor 11234 | 7 | 70 | $0.00 |
| eosinophils absolute | 1,018 | 10,180 | $0.99 |
| lung specialist near newbury park, thousand oaks, ca | 7 | 70 | $0.00 |